Cargando…
A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children
The diagnosis of idiopathic short stature (ISS) refers to children who are considerably shorter than average without any identified medical reason. The US Food and Drug Administration (FDA) authorised marketing of recombinant human growth hormone (hGH) for ISS in 2003, while the European Medicines A...
Autor principal: | Murano, Maria Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411515/ https://www.ncbi.nlm.nih.gov/pubmed/32056083 http://dx.doi.org/10.1007/s10728-020-00390-1 |
Ejemplares similares
-
Evaluation of craniofacial morphology in short-statured children: growth hormone deficiency versus idiopathic short stature
por: Kim, Ki Bong, et al.
Publicado: (2020) -
Comparison of Growth Hormone Treatment in Patients with Idiopathic Short Stature and Idiopathic Growth Hormone Deficiency
por: Kim, Seul Ah, et al.
Publicado: (2014) -
Effect of growth hormone treatment on children with idiopathic short stature and idiopathic growth hormone deficiency
por: Im, Minji, et al.
Publicado: (2017) -
Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
por: Ivama-Brummell, Adriana M., et al.
Publicado: (2023) -
Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature
por: Benabbad, Imane, et al.
Publicado: (2018)